EMA invites comments on consultation process for drug/device products
This article was originally published in Clinica
Executive Summary
The European Medicines Agency has launched for comment a 16-page draft guidance on how notified bodies consult the agency on products that combine devices with "an ancillary medicinal substance or an ancillary human blood derivate".
Register for our free email digests: